Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Executive Summary
- Satellos reported Q3 2025 financial results, posting a net loss of $5.8 M and cash balance of $34.6 M, down from $48.5 M year‑end 2024.
- The company completed IND filing in the U.S. and parallel global regulatory submissions to launch a Phase 2 trial of SAT‑3247 in pediatric DMD, and dosed the first patient in its long‑term adult follow‑up study (LT‑001).
- Mark Nawacki, former CEO of Searchlight Pharma, was appointed to Satellos’ Board of Directors to strengthen strategic leadership.
Key Details
- Board Appointment:
-
Mark Nawacki – co‑founder, president & former CEO of Searchlight Pharma – joined the Satellos Board in November 2025.
-
Regulatory Milestones:
- IND submitted to FDA (U.S.) for Phase 2 pediatric SAT‑3247 trial (ambulatory DMD children).
- Parallel filings made with UK, EU, Serbia, Australia; Health Canada filing on Nov 13 2025.
-
First patient enrollment in Phase 2 expected by end of calendar 2025.
-
Clinical Progress:
- Presented Phase 1b adult data at World Muscle Society Congress:
- Mean grip‑strength improvement – 118.6 % (dominant hand), 97.9 % (non‑dominant).
- Respiratory function (FVC) improved by 5.8 %.
- First patient dosed in open‑label LT‑001 adult study; study to assess long‑term safety, MRI muscle composition, functional outcomes.
-
Additional LT‑001 enrollment planned, including U.S. sites; data expected Q1 2026.
-
Financial Results (USD):
- Cash & equivalents: $34.6 M as of Sep 30 2025 (vs. $48.5 M at Dec 31 2024).
- Net loss for quarter: $5.8 M ($0.03 per share) vs. $6.6 M a year earlier.
- R&D expenses: $4.0 M (up from $2.4 M YoY), driven by clinical trial costs.
-
G&A expenses: $2.0 M (up from $1.3 M YoY), reflecting higher headcount and stock‑based compensation.
-
Outlook & Use of Funds:
- Cash decrease reflects net loss and increased deposits for Phase 2 trial execution.
- Company expects to fund ongoing clinical activities through existing cash runway; no new financing disclosed in this release.
Notable Quotes
“The second half of 2025 represents another important milestone for Satellos as we advance toward initiating the global Phase 2 pediatric study of SAT‑3247 and continue to generate meaningful data in adults with Duchenne,” – Wildon Farwell, M.D., Chief Medical Officer
“Mark’s extensive experience founding and developing organizations through disciplined growth, acquisitions, and licensing will add valuable perspective as we prepare for the next stage of SAT‑3247 development and Satellos’ continued growth.” – Frank Gleeson, Co‑founder & CEO